The regulators might be uncertain whether Moderna’s (MRNA) Covid-19 vaccine is suitable for younger people, but an FDA panel was unanimous in agreement when considering the use of its booster shot. The committee voted 19-0 in favor of a Spikevax booster to be administered at least 6 months following completion of the primary vaccines for individuals over 65, for those between ages 18 to 64 who are at risk either for medical reasons or via occupation and for people in long-term care.
https://www.tipranks.com/news/article/will-covid-19-booster-approval-boost-moderna-stock-analyst-weighs-in?utm_source=advfn.com&utm_medium=referral
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Nov 2021 to Dec 2021 Click Here for more Moderna Charts.
Moderna (NASDAQ:MRNA)
Historical Stock Chart
From Dec 2020 to Dec 2021 Click Here for more Moderna Charts.